Marla C. Dubinsky
YOU?
Author Swipe
View article: Bowel Urgency in Crohn's Disease: Bridging the Gap Between Patients and Healthcare Providers
Bowel Urgency in Crohn's Disease: Bridging the Gap Between Patients and Healthcare Providers Open
Bowel urgency (BU) is a prevalent and highly burdensome symptom among patients with inflammatory bowel disease. While BU is now recognized as a key symptom of ulcerative colitis, in the case of Crohn's disease (CD), it is often under-recog…
View article: The impact of inflammatory bowel disease on women’s health: a cross sectional study in India
The impact of inflammatory bowel disease on women’s health: a cross sectional study in India Open
IBD affects women across physical, reproductive, social, and financial domains. Culturally sensitive, multidisciplinary care models are essential to address these unmet needs.
Efficacy and Safety with Upadacitinib by Baseline Corticosteroid Use in Patients with Moderately to Severely Active Crohn’s Disease Open
Importance and Objective Upadacitinib, an oral, reversible Janus kinase inhibitor, is approved for the treatment of moderate-to-severe Crohn’s disease (CD). Limiting corticosteroid exposure is an important goal in treating CD. This posthoc…
Pregnancy Outcomes After Maternal or Paternal Exposure to Tofacitinib Across Clinical Programs Open
INTRODUCTION: This analysis reports updated pregnancy outcomes after tofacitinib exposure in patients with immune-mediated diseases. METHODS: Pregnancy/partner pregnancy cases from interventional studies were identified in Pfizer safety da…
View article: Long-Term Ozanimod Therapy in Patients With Moderately Active Ulcerative Colitis After Failure of 5-Aminosalicylic Acid
Long-Term Ozanimod Therapy in Patients With Moderately Active Ulcerative Colitis After Failure of 5-Aminosalicylic Acid Open
Background We evaluated the efficacy and safety of ozanimod after 5-aminosalicylic acid (5-ASA) failure in advanced therapy (AT)–naive patients with moderate ulcerative colitis (UC) in True North and its open-label extension (OLE). Methods…
View article: Integrating Intestinal Ultrasound to Clinical Trials in Patients With Crohn’s Disease: Opportunities and Challenges
Integrating Intestinal Ultrasound to Clinical Trials in Patients With Crohn’s Disease: Opportunities and Challenges Open
This narrative review summarizes the current knowledge on using intestinal ultrasonography (IUS) to evaluate disease activity in patients with Crohn’s disease (CD) and explores its potential role in clinical trials. Current trial endpoints…
View article: Etrasimod for the symptomatic relief of ulcerative colitis: a post-hoc analysis from the ELEVATE UC clinical programme
Etrasimod for the symptomatic relief of ulcerative colitis: a post-hoc analysis from the ELEVATE UC clinical programme Open
Objective Bothersome ulcerative colitis (UC) symptoms include stool frequency (SF), rectal bleeding (RB), abdominal pain and bowel urgency; symptomatic relief is a key treatment goal. Etrasimod is an oral, once-daily (QD), selective sphing…
Bowel urgency in ulcerative colitis: effect of baseline urgency and change in urgency in response to mirikizumab Open
Background Mirikizumab has demonstrated efficacy in moderately to severely active ulcerative colitis. A 1–2-point change in Urgency Numeric Rating Scale (NRS) score can be meaningful for patients. In these post-hoc analyses, we evaluated t…
View article: Effect of the Cervical Lesion Severity on Procedural and Clinical Outcomes after Endovascular Treatment of Acute Tandem Lesions: A Multicenter Study
Effect of the Cervical Lesion Severity on Procedural and Clinical Outcomes after Endovascular Treatment of Acute Tandem Lesions: A Multicenter Study Open
BACKGROUND Tandem lesions pose unique challenges in the endovascular treatment of acute ischemic stroke. We aimed to compare the clinical and procedural outcomes of patients with tandem lesions and extracranial internal carotid artery (ICA…
Achievement of long-term treatment goals in upadacitinib-treated patients with moderately to severely active ulcerative colitis: a post hoc analysis of phase 3 trial data Open
Background and Aims Comprehensive disease control is an important yet elusive treatment goal in ulcerative colitis (UC). We evaluated the effect of upadacitinib induction and maintenance treatment on composite clinical endpoints and normal…
Obefazimod in patients with moderate-to-severely active ulcerative colitis: efficacy and safety analysis from the 96-week open-label maintenance phase 2b study Open
Background and Aims Obefazimod is an oral small molecule that selectively enhances the expression of a single micro-RNA (miRNA), miR-124. Obefazimod has demonstrated safety and efficacy in patients with moderate-to-severely active ulcerati…
View article: Symptom Resolution and Meaningful Improvement in Quality of Life With Risankizumab in Patients With Ulcerative Colitis: Post Hoc Analysis of the Randomized INSPIRE and COMMAND Studies
Symptom Resolution and Meaningful Improvement in Quality of Life With Risankizumab in Patients With Ulcerative Colitis: Post Hoc Analysis of the Randomized INSPIRE and COMMAND Studies Open
INTRODUCTION: Patients with ulcerative colitis (UC) experience disruptive symptoms that can impair quality of life (QoL). This study examined the effect of risankizumab (RZB) induction and maintenance treatment on symptom resolution and he…
View article: Long-Term Effectiveness and Durability of COVID-19 Vaccination among Patients with Inflammatory Bowel Disease
Long-Term Effectiveness and Durability of COVID-19 Vaccination among Patients with Inflammatory Bowel Disease Open
Background and Aims COVID-19 vaccination prevents severe disease in most patients with IBD, but immunosuppressive medications can blunt serologic response. We followed adults with IBD for >1-year post-COVID-19 vaccination to describe facto…
View article: Humoral immune response and safety of SARS-CoV-2 vaccination in very early onset inflammatory bowel disease
Humoral immune response and safety of SARS-CoV-2 vaccination in very early onset inflammatory bowel disease Open
Children with very early onset inflammatory bowel disease (VEO-IBD) may respond differently to coronavirus disease 2019 (COVID-19) immunization compared to healthy children or other patients with IBD. We recruited children with VEO-IBD <6 …
View article: Efficacy and Safety of Etrasimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Baseline Modified Mayo Score: A Post Hoc Analysis From the Phase 3 ELEVATE UC Clinical Program
Efficacy and Safety of Etrasimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Baseline Modified Mayo Score: A Post Hoc Analysis From the Phase 3 ELEVATE UC Clinical Program Open
Background Etrasimod is an oral, once daily, selective sphingosine 1-phosphate (S1P)1,4,5 receptor modulator for the treatment of moderately to severely active ulcerative colitis (UC). This post hoc analysis of the ELEVATE UC clinical prog…
View article: Ustekinumab Drug Clearance Is Better Associated with Disease Control than Serum Trough Concentrations in a Prospective Cohort of Inflammatory Bowel Disease
Ustekinumab Drug Clearance Is Better Associated with Disease Control than Serum Trough Concentrations in a Prospective Cohort of Inflammatory Bowel Disease Open
Background/Objectives: This study aimed to compare the association of ustekinumab (UST) drug clearance (CL) and trough drug concentrations with disease activity in patients with inflammatory bowel diseases (IBDs). Methods: A prospective co…
View article: EXIT INTERVIEWS EXPLORING PATIENTS’ EXPERIENCE OF CHANGES IN THEIR ABDOMINAL PAIN DURING THE PHASE 3 CLINICAL TRIAL OF MIRIKIZUMAB FOR TREATMENT OF MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE
EXIT INTERVIEWS EXPLORING PATIENTS’ EXPERIENCE OF CHANGES IN THEIR ABDOMINAL PAIN DURING THE PHASE 3 CLINICAL TRIAL OF MIRIKIZUMAB FOR TREATMENT OF MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE Open
INTRODUCTION Abdominal pain (AP) is the most common symptom in patients with Crohn’s disease (CD) and negatively impacts quality of life. We qualitatively examined the changes in AP among participants with moderately to severely active CD …
View article: Inflammatory disease microbiomes share a functional pathogenicity predicted by C-reactive protein
Inflammatory disease microbiomes share a functional pathogenicity predicted by C-reactive protein Open
We examine disease-specific and cross-disease functions of the human gut microbiome by colonizing germ-free mice, at risk for inflammatory arthritis, colitis, or neuroinflammation, with over 100 human fecal microbiomes from subjects with r…
Impact of age at diagnosis on college adjustment in students with inflammatory bowel disease Open
Objectives Little is known about the experience of college students with inflammatory bowel disease (IBD) and the factors associated with transition readiness, academic adjustment, and alternatively, those associated with academic hardship…
Cardiovascular events observed among patients in the etrasimod clinical programme: an integrated safety analysis of patients with moderately to severely active ulcerative colitis Open
Objective Etrasimod is an oral, once-daily, selective sphingosine 1-phosphate (S1P) 1,4,5 receptor modulator for the treatment of moderately to severely active ulcerative colitis (UC). S1P 1 receptor expression on cardiac cells is involved…
View article: P0252 Mild Crohn’s disease is associated with altered sphingolipid metabolism and reduced neutrophilic inflammation
P0252 Mild Crohn’s disease is associated with altered sphingolipid metabolism and reduced neutrophilic inflammation Open
Background Around 20-30% of patients with Crohn's disease (CD) experience a mild disease course. However, identifying patients likely to maintain a mild course is challenging. This study aimed to identify molecular features of mild CD by e…
Perspectives on Contraception, Pregnancy, and Reproductive Health Counseling from Young Women With Inflammatory Bowel Disease Open
Background/Aims Active inflammatory bowel disease (IBD) increases the risk of pregnancy complications and contraceptive side effects, and contraceptive use may impact the clinical course of IBD. Although young people are at elevated risk f…
View article: Exit Interviews Exploring Patients’ Experience of Change in Crohn’s Disease Symptoms During the Mirikizumab Phase 3 Clinical Trial In Adult Patients With Moderately-to-Severely Crohn’s Disease
Exit Interviews Exploring Patients’ Experience of Change in Crohn’s Disease Symptoms During the Mirikizumab Phase 3 Clinical Trial In Adult Patients With Moderately-to-Severely Crohn’s Disease Open
Background Exit interviews with patients who completed the Phase 3 VIVID-1 mirikizumab clinical trial for moderately-to-severely active Crohn’s disease explored the content validity of bowel urgency, stool frequency, and abdominal pain pat…
View article: Low Incidence of Macular Edema and Other Ocular Events in the Etrasimod Development Program
Low Incidence of Macular Edema and Other Ocular Events in the Etrasimod Development Program Open
Background and Aims Sphingosine 1-phosphate receptor modulators have been associated with an increased risk of macular edema. Etrasimod is an oral, once-daily, selective sphingosine 1-phosphate1,4,5 receptor modulator. Methods We report th…